Trial
NCT02912455
CARAT: Canagliflozin vs. Placebo for Post Bariatric Patients With Persistent Type 2 Diabetes
Phase IVTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
The Cleveland Clinic
Collaborators
Janssen Scientific Affairs, LLC
Condition
Diabetes Mellitus, Type 2
Intervention
canagliflozin
Why stopped
Study was terminated due to difficulty with reaching enrollment goals
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-11-20